Literature DB >> 28717844

Application of the Biopsy-Sparing ESPGHAN Guidelines for Celiac Disease Diagnosis in Adults: A Real-Life Study.

Konstantinos Efthymakis1, Mariaelena Serio1, Angelo Milano1, Francesco Laterza1, Antonella Bonitatibus1, Marta Di Nicola2, Matteo Neri3.   

Abstract

BACKGROUND: Current adult celiac disease diagnosis requires histological confirmation. However, pediatric guidelines have proposed biopsy-sparing algorithms. AIMS: To explore the applicability of the ESPGHAN criteria and assess the accuracy of serology in predicting disease in adults.
METHODS: We evaluated 234 consecutive adults showing elevated anti-tTG titers, EMA-positivity, and genetic susceptibility. Patients underwent upper endoscopy with duodenal biopsy. We determined optimal anti-tTG cutoff levels using ROC curves.
RESULTS: Mean anti-tTG levels were 71.1 ± 66.5 U/ml; mean normalized levels were 14.8 ± 14.1 × ULN (mean ± SD). Partial/total villous atrophy was present in 36%/55% of cases, respectively. Anti-tTG levels correlated with histology (r s = 0.397, p < 0.001). AUC was similar before and after normalization (0.803 vs 0.807). Applying the ESPGHAN criterion (≥10 × ULN), we calculated a 97.66% PPV. ROC curve analysis showed an optimal cutoff of ≥16 × ULN, with a PPV of 98.86%. Eleven different assays were used for anti-tTG titer determination: Two were prevalent, labeled A (n = 141) and B (n = 59). They performed differently regarding disease prediction (AUC = 0.689 vs 0.925, p < 0.01), showing distinct optimal cutoff values (14.3 × ULN vs 3.7 × ULN), even after standardization (-0.14 vs -1.2).
CONCLUSION: In adult symptomatic patients showing EMA-positivity and genetic susceptibility, anti-tTG titers correlated with histology. ESPGHAN criteria performed similarly to previous studies. However, a calculated 16 × ULN cutoff showed an improved PPV. Among prevalent assays, PPV peaked differently both after normalization and standardization, indicating intrinsic differences in performance, thus preventing uniform prediction of disease in a real-life setting. Assay-specific optimal cutoffs seem possible, but would complicate diagnostic criteria. However, biopsy-sparing strategies in adults could prove useful in challenging patients.

Entities:  

Keywords:  Anti-tTG; Biopsy-sparing; Celiac disease; Duodenal biopsy; ESPGHAN guidelines; Small intestine; Villous atrophy

Mesh:

Year:  2017        PMID: 28717844     DOI: 10.1007/s10620-017-4672-1

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  20 in total

1.  Coeliac disease: a biopsy is not always necessary for diagnosis.

Authors:  P G Hill; G K T Holmes
Journal:  Aliment Pharmacol Ther       Date:  2008-01-11       Impact factor: 8.171

2.  Identification of a serum transglutaminase threshold value for the noninvasive diagnosis of symptomatic adult celiac disease patients: a retrospective study.

Authors:  Marco Di Tola; Mariacatia Marino; Simone Goetze; Rossella Casale; Sara Di Nardi; Raffaele Borghini; Giuseppe Donato; Antonio Tiberti; Antonio Picarelli
Journal:  J Gastroenterol       Date:  2016-02-29       Impact factor: 7.527

3.  The presence of anti-endomysial antibodies and the level of anti-tissue transglutaminases can be used to diagnose adult coeliac disease without duodenal biopsy.

Authors:  R Tortora; N Imperatore; P Capone; G D De Palma; G De Stefano; N Gerbino; N Caporaso; A Rispo
Journal:  Aliment Pharmacol Ther       Date:  2014-09-28       Impact factor: 8.171

4.  Clinics of coeliac disease in children in the 2000s.

Authors:  E Savilahti; K-L Kolho; M Westerholm-Ormio; M Verkasalo
Journal:  Acta Paediatr       Date:  2010-02-25       Impact factor: 2.299

5.  Diagnosis of coeliac disease in children younger than 2 years.

Authors:  Zrinjka Mišak; Iva Hojsak; Oleg Jadrešin; Alemka Jaklin Kekez; Slaven Abdović; Sanja Kolaček
Journal:  J Pediatr Gastroenterol Nutr       Date:  2013-02       Impact factor: 2.839

6.  Antigliadin immunoglobulin A best in finding celiac disease in children younger than 18 months of age.

Authors:  Carina Lagerqvist; Ingrid Dahlbom; Tony Hansson; Erik Jidell; Per Juto; Per Olcén; Hans Stenlund; Olle Hernell; Anneli Ivarsson
Journal:  J Pediatr Gastroenterol Nutr       Date:  2008-10       Impact factor: 2.839

7.  Age-related clinical, serological, and histopathological features of celiac disease.

Authors:  Santiago Vivas; Jose M Ruiz de Morales; Marisa Fernandez; Mercedes Hernando; Blanca Herrero; Javier Casqueiro; Santiago Gutierrez
Journal:  Am J Gastroenterol       Date:  2008-08-12       Impact factor: 10.864

8.  Prediction of clinical and mucosal severity of coeliac disease and dermatitis herpetiformis by quantification of IgA/IgG serum antibodies to tissue transglutaminase.

Authors:  Ingrid Dahlbom; Ilma R Korponay-Szabó; Judit B Kovács; Zsuzsanna Szalai; Markku Mäki; Tony Hansson
Journal:  J Pediatr Gastroenterol Nutr       Date:  2010-02       Impact factor: 2.839

9.  Duodenal biopsy may be avoided when high transglutaminase antibody titers are present.

Authors:  Santiago Vivas; Jose G Ruiz de Morales; Sabino Riestra; Laura Arias; Dolores Fuentes; Noemi Alvarez; Sara Calleja; Mercedes Hernando; Blanca Herrero; Javier Casqueiro; Luis Rodrigo
Journal:  World J Gastroenterol       Date:  2009-10-14       Impact factor: 5.742

10.  Strongly positive tissue transglutaminase antibodies are associated with Marsh 3 histopathology in adult and pediatric celiac disease.

Authors:  Matthew R Donaldson; Linda S Book; Kristin M Leiferman; John J Zone; Susan L Neuhausen
Journal:  J Clin Gastroenterol       Date:  2008-03       Impact factor: 3.062

View more
  8 in total

1.  No-biopsy pathway following the interim BSG guidance reliably diagnoses adult coeliac disease.

Authors:  Richard David Johnston; Ying Jenny Chan; Tayyib Mubashar; Joseph Robert Bailey; Siba Prosad Paul
Journal:  Frontline Gastroenterol       Date:  2020-10-06

2.  Is duodenal biopsy always necessary for the diagnosis of coeliac disease in adult patients with high anti-tissue transglutaminase (TTG) antibody titres?

Authors:  Junaid Beig; Kamran Rostami; David T S Hayman; Summer Hassan; Stephen Gerred; Ravinder Ogra
Journal:  Frontline Gastroenterol       Date:  2021-06-25

Review 3.  Diagnosis of Celiac Disease: Taking a Bite Out of the Controversy.

Authors:  Justine M Turner
Journal:  Dig Dis Sci       Date:  2018-06       Impact factor: 3.199

Review 4.  The Role of Gastrointestinal-Related Fatty Acid-Binding Proteins as Biomarkers in Gastrointestinal Diseases.

Authors:  Shaun S C Ho; Jacqueline I Keenan; Andrew S Day
Journal:  Dig Dis Sci       Date:  2019-09-16       Impact factor: 3.199

5.  Accuracy of a no-biopsy approach for the diagnosis of coeliac disease across different adult cohorts.

Authors:  Hugo A Penny; Suneil A Raju; Michelle S Lau; Lauren Js Marks; Elisabeth Mr Baggus; Julio C Bai; Gabrio Bassotti; Hetty J Bontkes; Antonio Carroccio; Mihai Danciu; Mohammad H Derakhshan; Arzu Ensari; Azita Ganji; Peter H R Green; Matt W Johnson; Sauid Ishaq; Benjamin Lebwohl; Adam Levene; Roxana Maxim; Hamid Mohaghegh Shalmani; Mohammad Rostami-Nejad; David Rowlands; Irene A Spiridon; Amitabh Srivastava; Umberto Volta; Vincenzo Villanacci; Graeme Wild; Simon S Cross; Kamran Rostami; David S Sanders
Journal:  Gut       Date:  2020-11-02       Impact factor: 23.059

6.  A No-Biopsy Approach for the Diagnosis of Celiac Disease in Adults: Can It Be Real?

Authors:  Ahmed Ramiz Baykan; Serkan Cerrah; Sedat Ciftel; Mete Koray Vural; Elmas Kasap
Journal:  Cureus       Date:  2022-07-03

7.  Non-Biopsy Serology-Based Diagnosis of Celiac Disease in Adults Is Accurate with Different Commercial Kits and Pre-Test Probabilities.

Authors:  Venla Ylönen; Katri Lindfors; Marleena Repo; Heini Huhtala; Valma Fuchs; Päivi Saavalainen; Alex Musikka; Kaija Laurila; Katri Kaukinen; Kalle Kurppa
Journal:  Nutrients       Date:  2020-09-08       Impact factor: 5.717

Review 8.  Serologic diagnosis of celiac disease: May it be suitable for adults?

Authors:  Giuseppe Losurdo; Milena Di Leo; Edoardo Santamato; Monica Arena; Maria Rendina; Carmelo Luigiano; Enzo Ierardi; Alfredo Di Leo
Journal:  World J Gastroenterol       Date:  2021-11-14       Impact factor: 5.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.